Efpeglenatide: The Gila-Monster-Derived, Once-Weekly GLP-1 With Landmark Heart and Kidney Data - How Hanmi's Exendin-Fc Injection Works and Where It Stands in 2026 (August 18, 2026)
Table of Contents
- A GLP-1 that doesn't start from human GLP-1
- The engineering: exendin-4 stitched to an antibody
- What it does in the body
- AMPLITUDE-O: the trial that put it on the map
- The kidney signal that got researchers' attention
- Beyond the outcomes trial: sugar and weight
- The Sanofi detour
- Where it stands in 2026
- How to think about it next to the big names
- The bottom line and the cautions
A GLP-1 that doesn't start from human GLP-1
Nearly every GLP-1 medicine you have heard of - semaglutide (Ozempic, Wegovy), liraglutide, dulaglutide - is engineered by taking the human hormone glucagon-like peptide-1 and tweaking it so the body cannot break it down quickly. Efpeglenatide is different at the root. Its active piece is exendin-4, a 39-amino-acid peptide first isolated from the saliva of the Gila monster, a venomous desert lizard. Exendin-4 happens to switch on the human GLP-1 receptor while being naturally resistant to DPP-4, the enzyme that chews up native GLP-1 within minutes. That venom-derived scaffold is the same one behind the older drug exenatide, but efpeglenatide adds an engineering trick that makes it last far longer.
The engineering: exendin-4 stitched to an antibody
To turn a short-lived peptide into a once-weekly shot, Hanmi Pharmaceutical used its LAPSCOVERY (Long-Acting Protein/Peptide Discovery) platform. A single amino-acid-modified exendin-4 is joined to the Fc region of a human immunoglobulin G4 (IgG4) antibody through a small mini-polyethylene-glycol (mini-PEG) linker. The bulky antibody fragment slows the kidney's clearance of the drug and lets it recycle through cells, stretching the half-life so one subcutaneous injection covers a full week - some studies even tested once every two weeks. This is a fundamentally different half-life strategy than semaglutide's, which relies on a fatty-acid chain that binds albumin. Efpeglenatide shows there is more than one way to build a durable GLP-1.
What it does in the body
Once it reaches the GLP-1 receptor, efpeglenatide behaves like the rest of the class. It boosts insulin release from the pancreas in a glucose-dependent way - meaning mostly when blood sugar is high, which keeps hypoglycemia risk low - and it dials down glucagon, the hormone that raises blood sugar. It slows how fast the stomach empties and acts on appetite centers in the brain, so people feel full sooner and eat less. The result is lower blood glucose and meaningful weight loss, the two effects that have made GLP-1 drugs a phenomenon in both diabetes and obesity.
AMPLITUDE-O: the trial that put it on the map
Efpeglenatide's headline moment came in 2021 with AMPLITUDE-O, published in the New England Journal of Medicine. Researchers randomized 4,076 adults with type 2 diabetes who also had cardiovascular disease, or kidney disease plus another risk factor, to weekly efpeglenatide (4 mg or 6 mg) or placebo on top of their usual care. Over a median of about 1.8 years, major adverse cardiovascular events - the composite of heart attack, stroke or cardiovascular death - happened in 7.0% of the efpeglenatide group versus 9.2% on placebo. That is a hazard ratio of 0.73, a 27% relative reduction, and it was statistically significant for superiority.
The kidney signal that got researchers' attention
Just as striking was the kidney result. A composite kidney outcome - worsening kidney function or new/worsening protein in the urine - occurred in 13.0% of the efpeglenatide group versus 18.4% on placebo, a hazard ratio of 0.68. That is one of the clearest kidney signals seen for a GLP-1 receptor agonist. Crucially, the heart and kidney benefits held up whether or not patients were also taking an SGLT2 inhibitor - the other big cardiorenal drug class - suggesting the two could add value on top of each other rather than one masking the other. AMPLITUDE-O helped reframe GLP-1 drugs as cardiorenal medicines, not just glucose-lowering ones.
Beyond the outcomes trial: sugar and weight
The rest of the AMPLITUDE program filled in the everyday picture. AMPLITUDE-M (Diabetes Care 2022) tested efpeglenatide by itself against placebo in type 2 diabetes and showed dose-related drops in HbA1c and body weight. Earlier Phase 2 work, including a randomized study in adults who had obesity but not diabetes (PubMed 31264757), demonstrated significant, dose-dependent weight loss - the data that justify developing efpeglenatide as a stand-alone obesity drug. A 2025 systematic review concluded that across trials its glucose- and weight-lowering looked broadly comparable to liraglutide and semaglutide in the populations studied, with the usual GLP-1 tolerability profile.
The Sanofi detour
Efpeglenatide's path to market has been anything but straight. Hanmi licensed the drug to Sanofi in 2015, and Sanofi ran the large AMPLITUDE Phase 3 program. But in 2020 Sanofi stepped back from cardiovascular and metabolic primary-care drugs and returned the rights to Hanmi - a strategic retreat, not a safety problem. That handoff is why a molecule with a positive NEJM cardiovascular outcomes trial spent several years without a clear commercial owner. Hanmi picked it back up and re-pointed it at the fastest-growing indication in medicine: obesity.
Where it stands in 2026
Hanmi is now advancing efpeglenatide for obesity and overweight. The company has reported completing enrollment in its Phase 3 obesity program and has publicly moved up its timeline, targeting a first commercial launch in South Korea in the second half of 2026. Hanmi has framed efpeglenatide as offering weight loss in the range of the leading GLP-1s while carrying its distinctive cardiovascular and kidney evidence - though it is worth stressing that head-to-head superiority over semaglutide or tirzepatide on weight has not been established, and the cardiorenal data come from high-risk diabetes patients, not the general obesity population.
How to think about it next to the big names
Efpeglenatide sits in a crowded field. Semaglutide and tirzepatide dominate on weight loss; oral agents like orforglipron are racing to remove the needle; and dual and triple agonists like retatrutide and survodutide are pushing efficacy higher. Efpeglenatide's pitch is different: a once-weekly injection from a non-human GLP-1 scaffold, with proven heart and kidney outcomes and the potential to be a lower-cost option that widens access - especially in markets outside the U.S. where it may launch first. It also keeps interesting company within Hanmi's own pipeline, since the same LAPSCOVERY platform underlies the GLP-1/glucagon dual agonists efinopegdutide and efocipegtrutide.
The bottom line and the cautions
Efpeglenatide is a genuinely distinctive GLP-1: venom-derived exendin-4, antibody-Fc half-life extension, and a rare pairing of significant cardiovascular and kidney outcome data. But it is still investigational - not approved by the FDA or EMA - and its side-effect profile is the familiar GLP-1 one: mostly nausea, vomiting and other gastrointestinal effects that ease with slow dose escalation, plus the class warnings around thyroid C-cell tumors (seen in rodents), pancreatitis and gallbladder disease. Anything sold online as 'efpeglenatide' or 'HM11260C' outside a clinical trial is unverified and should be treated as unsafe. This article is educational and not medical advice; treatment decisions belong with a qualified clinician.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] Gerstein HC, Sattar N, Rosenstock J, et al. - Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes (AMPLITUDE-O), New England Journal of Medicine (2021) Source
- [2] Effect of Efpeglenatide on Cardiovascular Outcomes (AMPLITUDE-O) - ClinicalTrials.gov, NCT03496298 Source
- [3] Frias JP, Choi J, Rosenstock J, et al. - Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes (AMPLITUDE-M), Diabetes Care (2022) Source
- [4] Efficacy and Safety of Efpeglenatide in Patients With Type 2 Diabetes and Obesity: A Systematic Review, PMC (2025) Source
- [5] Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study, PubMed 31264757 Source
- [6] Hanmi Pharm advances launch of obesity drug efpeglenatide to late 2026 - Korea Biomedical Review Source
Related Articles
A comprehensive guide to GLP-1 receptor agonists — how they work, what sets them apart, and where the science is heading.
The Oral GLP-1 Pill Race Widens: Conveglipron (HDM1002) Joins Orforglipron in the Hunt for a Needle-Free Weight-Loss Drug — June 15, 2026
Conveglipron (HDM1002) is an oral, once-daily small-molecule GLP-1 receptor agonist from Huadong Medicine now in Phase 2 for obesity and Phase 3 for type 2 diabetes. Here's how the GLP-1 'pill' race is shaping up against orforglipron and danuglipron — and why an oral small molecule is not the same thing as a peptide.
Efinopegdutide (MK-6024): The GLP-1/Glucagon Dual That Beat Semaglutide on Liver Fat (July 22, 2026)
GLP-1 drugs like semaglutide shrink liver fat mostly by making you lose weight. Efinopegdutide adds a glucagon arm that burns fat inside the liver directly - and in a head-to-head Phase 2a trial it cut liver fat by 72.7% versus semaglutide's 42.3% at matched weight loss. Here is how the oxyntomodulin-based dual agonist works, why Merck redirected a twice-shelved Hanmi molecule at MASH, and what still has to be proven on biopsy.